benzothiophene | Page 77 of 647 | Heterocyclic Building Blocks-Benzothiophene

Okun, R’s team published research in Postgraduate medical journal in 1979 | CAS: 40180-04-9

Postgraduate medical journal published new progress in MEDLINE about 40180-04-9, 40180-04-9 belongs to class benzothiophene, name is 2-(2,3-Dichloro-4-(thiophene-2-carbonyl)phenoxy)acetic acid, and the molecular formula is C13H8Cl2O4S, Application In Synthesis of 40180-04-9.

Okun, R published the artcileA double-blind study of tienilic acid with two year follow-up of patients with mild to moderate essential hypertension., Application In Synthesis of 40180-04-9, the main research area is .

In a double-blind study, thirty patients having mild to moderate essential hypertension were randomly assigned to a six week regimen of either tienilic acid, hydrochlorothiazide, or placebo. Blood pressure was significantly reduced with tienilic acid and hydrochlorothiazide although more so with tienilic acid. Serum uric acid declined strikingly with tienilic acid and increased significantly with hydrochlorothiazide. Serum potassium declined slightly with tienilic acid but more so with hydrochlorothiazide. Serum creatinine and blood urea nitrogen increased slightly more with tienilic acid than with hydrochlorothiazide. There were no clinical adverse effects to any of the medications during this study. Twenty-four months of continuous administration of tienilic acid revealed maintenance of blood pressure effect, but with slight increases in blood urea nitrogen, serum creatinine and uric acid and slight decreases in serum potassium as compared to six weeks administration. Tienilic acid appears to be a useful new antihypertensive agent. The hypouricaemic effect is profound and strongly suggests the need for continuing evaluation of this compound because of its unique combination of diuretic, antihypertensive and hypouricaemic properties.

Referemce:
Benzothiophene – Wikipedia,
Benzothiophene | C8H6S – PubChem

Andersson, O’s team published research in Postgraduate medical journal in 1979 | CAS: 40180-04-9

Andersson, O published the artcileTienilic acid in mild to moderate hypertension., Computed Properties of 40180-04-9, the main research area is .

Tienilic acid has blood pressure lowering properties alone and in combined treatment with beta-adrenergic blocking agents; 250 mg of tienilic acid seems to correspond to 50 mg of hydrochlorothiazide. Tienilic acid effectively reduces serum urate and has no marked or rapid effect on potassium balance. During short-term treatment, no impairment of glucose tolerance was found.

Referemce:
Benzothiophene – Wikipedia,
Benzothiophene | C8H6S – PubChem

Morgan, A’s team published research in Postgraduate medical journal in 1979 | CAS: 40180-04-9

Morgan, A published the artcileThe use of tienilic acid in nephrotic syndrome: a clinical study., Application In Synthesis of 40180-04-9, the main research area is .

The diuretic and uricosuric activities of tienilic acid 250–50 mg daily over a minimum six week period have been studied in seven patients with the nephrotic syndrome secondary to glomerulonephritis proven by renal biopsy. Tienilic acid failed to control oedema in one patient who had to be withdrawn. In the six other patients a hypouricaemic effect with increased urate clearance was noted. No consistent effects were noted with respect to the serum cholesterol and triglyceride concentrations. No side effects were observed. It is concluded that in nephrotic patients tienilic acid behaves as a mild diuretic with consistent hypouricaemic and uricosuric effects.

Referemce:
Benzothiophene – Wikipedia,
Benzothiophene | C8H6S – PubChem

Pearson, R M’s team published research in Postgraduate medical journal in 1979 | CAS: 40180-04-9

Pearson, R M published the artcilePropranolol and tienilic acid in essential hypertension., Quality Control of 40180-04-9, the main research area is .

Sixteen patients with moderately severe essential hypertension completed a double-blind crossover trial with four treatment periods each lasting for six weeks. They received in random order, placebo; tienilic acid 250 mg/day; propranolol 80 mg b.d.; and tienilic acid 250 mg/day and propranolol 80 mg b.d. in combination. Mean blood pressure in the lying position was 169/98 mmHg on placebo, 157/94 mmHg on tienilic acid, 159/90 mmHg on propranolol and 142/86 mmHg on the combination of tienilic acid and propranolol. The effects of tienilic acid and propranolol on blood pressure were additive and there was no evidence of any interaction. The onset of the hypotensive effect of tienilic acid was gradual while the effect of propranolol was maximal within 2 weeks of the start of treatment. Tienilic acid produced a significant reduction in serum urate from 0.33 mmol/l to 0.18 mmol/l. The combination of tienilic acid and propranolol in the doses used in the trial was effective and acceptable in the reduction of raised blood pressure.

Referemce:
Benzothiophene – Wikipedia,
Benzothiophene | C8H6S – PubChem

Frohlich, E D’s team published research in Postgraduate medical journal in 1979 | CAS: 40180-04-9

Frohlich, E D published the artcileAntihypertensive and renal effects of tienilic acid., SDS of cas: 40180-04-9, the main research area is .

Tienilic acid, a diuretic agent effective at the cortical diluting segment of the distal tubule, has been found to have equivalent antihypertensive action in a dose of 250 mg twice daily to hydrochlorothiazide in a dose of 50 mg twice daily. Tienilic acid reduced arterial pressure without diminishing renal plasma flow or endogenous creatinine clearance; moreover, it did so whilst achieving hypouricaemia through a uricosuric effect. Hypokalaemia was observed but corrected by supplemental potassium. A transient but reversible, slight elevation in serum creatinine concentration and significant hypertriglyceridaemia were also observed. In conclusion, tienilic acid seems to be a novel diuretic, well-suited for the patient with hypertension, particularly if there is coincidental gout or coexisting hyperuricaemia.

Referemce:
Benzothiophene – Wikipedia,
Benzothiophene | C8H6S – PubChem

Kerr, H D’s team published research in Annals of emergency medicine in 1984 | CAS: 40180-04-9

Annals of emergency medicine published new progress in MEDLINE about 40180-04-9, 40180-04-9 belongs to class benzothiophene, name is 2-(2,3-Dichloro-4-(thiophene-2-carbonyl)phenoxy)acetic acid, and the molecular formula is C13H8Cl2O4S, Recommanded Product: 2-(2,3-Dichloro-4-(thiophene-2-carbonyl)phenoxy)acetic acid.

Kerr, H D published the artcileVocal cord hematomas complicating anticoagulant therapy., Recommanded Product: 2-(2,3-Dichloro-4-(thiophene-2-carbonyl)phenoxy)acetic acid, the main research area is .

Described are the cases of two patients who presented with vocal cord hematomas consequent to poor control of anticoagulation. Both patients presented with hoarseness and cough. One required intubation due to respiratory obstruction. Vocal cord hematomas should be considered in patients who present with upper airway symptoms while anticoagulated.

Referemce:
Benzothiophene – Wikipedia,
Benzothiophene | C8H6S – PubChem

Beg, M A’s team published research in Postgraduate medical journal in 1979 | CAS: 40180-04-9

Beg, M A published the artcileSafety of tienilic acid., Category: benzothiophene, the main research area is .

The safety and efficacy of tienilic acid have been evaluated in studies of patients with mild to moderate essential hypertension, salt and water retention states and hyperuricaemia associated with gout. During the course of these studies 675 patients were treated with tienilic acid, 310 were treated with hydrochlorothiazide, 43 were treated with probenecid and 34 were treated with placebo. Overall, adverse reactions characterized as probably drug-related or questinably drug-related were reported in 28% of patients treated with tienilic acid, 24% treated with hydrochlorothiazide, 25% of patients treated with probenecid and 33% treated with placebo. The side effects encountered were mild in severity, reversible and represented extensions of the pharmacological activity of tienilic acid, hydrochlorothiazide and probenecid. These initial studies demonstrate that tienilic acid is safe and effective in the treatment of mild to moderate essential hypertension, salt and water retention states, including oedema associated with congestive cardiac failure or mild to moderate renal dysfunction, and in the management of elevated serum uric acid levels associated with gout.

Referemce:
Benzothiophene – Wikipedia,
Benzothiophene | C8H6S – PubChem

McMahon, F G’s team published research in Postgraduate medical journal in 1979 | CAS: 40180-04-9

McMahon, F G published the artcileThe hypouricaemic effect of tienilic acid: experience in patients with hyperuricaemia., Product Details of C13H8Cl2O4S, the main research area is .

The anti-hypertensive effect of 250 mg tienilic acid was comparable to that of 50 mg hydrochlorothiazide. Unlike hydrochlorothiazide, tienilic acid caused a statistically significant decrease in the serum uric acid values. Clinically non-significant rises in blood urea nitrogen and serum creatinine occurred with both diuretics. The hypouricaemic effect of tienilic acid given in a daily dose of 125 mg was significantly greater than that of 500 mg probenecid. Glucose tolerance in patients with mild maturity onset diabetes mellitus deteriorated with both tienilic acid and hydrochlorothiazide treatments with no statistically significant difference noted between the two treatments. Tienilic acid was well tolerated and no clinically significant haematological or biochemical abnormalities were noted.

Referemce:
Benzothiophene – Wikipedia,
Benzothiophene | C8H6S – PubChem

Dubb, J W’s team published research in Postgraduate medical journal in 1979 | CAS: 40180-04-9

Dubb, J W published the artcileTienilic acid: pharmacokinetics, salicylate interaction and creatinine secretion studies., HPLC of Formula: 40180-04-9, the main research area is .

Tienilic acid is a diuretic-uricosuric compound whose natriuretic site of action is in the cortical diluting segment of the distal nephron. Oral doses of 250 mg given to normal human volunteers provided peak blood levels of 10–11 micrograms/ml at 3–4 hours after administration. Approximately 40% of the dose was recovered in 24 hours, 30% as the parent compound and 10% as the alcohol and diacid metabolites. A 650 mg dose of acetylsalicylic acid significantly decreased the uricosuric effect of tienilic acid by inhibiting uric acid secretion. Urine pH fell significantly with tienilic acid administration. Tienilic acid inhibited salicylate excretion by either competition for tubular secretion or by increasing passive, pH dependent reabsorption. In normal subjects given a creatinine load, tienilic acid did not inhibit creatinine secretion.

Referemce:
Benzothiophene – Wikipedia,
Benzothiophene | C8H6S – PubChem

Freis, E D’s team published research in Postgraduate medical journal in 1979 | CAS: 40180-04-9

Freis, E D published the artcileDouble-blind assessment of tienilic acid in essential hypertension., Application In Synthesis of 40180-04-9, the main research area is .

The antihypertensive effectiveness of tienilic acid in doses of 250 mg once and twice daily was compared to hydrochlorothiazide 50 mg once and twice per day in a randomized double-blind trial lasting six weeks. Blood pressure fell significantly and to a similar extent with the larger dose of both drugs. This was accompanied by a slight decrease in body weight and serum potassium concentration and a slight increase in serum creatinine and blood urea nitrogen. The magnitude of these changes was similar with both drugs. Unlike hydrochlorothiazide, however, the administration of tienilic acid was associated with a marked drop in the concentration of serum uric acid. No disturbing side effects or evidence of serious toxicity were noted during treatment with the new drug.

Referemce:
Benzothiophene – Wikipedia,
Benzothiophene | C8H6S – PubChem